Patents by Inventor Xiaowei Duan

Xiaowei Duan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FGFR4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20220185811
    Abstract: The invention relates to an FGFR4 kinase inhibitor, and the preparation method and use thereof. The invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, solvate, polymorph or tautomer thereof, and use thereof in the manufacture of a medicament for the treatment of an FGFR4 mediated disease.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 16, 2022
    Inventors: Jinghan WANG, Jinsuo YAO, Xiaowei DUAN, Baokun YUAN, Xijie LIU, Nan JIAO, Wangyang MIN, Ying SUN, Chang LU, Yinghui SUN, Jiuqing ZHANG, Yeling JI, Deng HOU
  • Iridinesulfonamide compound and use method thereof
    Patent number: 11203586
    Abstract: An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: December 21, 2021
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
    Inventors: Li Zhu, Yanqing Yang, Liguang Dai, Xiaowei Duan, Zhao Yang, Hui Zhang, Yuandong Hu, Yong Peng, Yongxin Han, Rui Zhao, Xin Tian, Shanchun Wang
  • Sultam compound and application method thereof
    Patent number: 11111240
    Abstract: Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: September 7, 2021
    Assignees: Chai Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
    Inventors: Li Zhu, Xiaowei Duan, Liguang Dai, Zhao Yang, Yanqing Yang, Hui Zhang, Yuandong Hu, Yong Peng, Yongxin Han, Rui Zhao, Xin Tian, Shanchun Wang
  • Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
    Patent number: 11098060
    Abstract: The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: August 24, 2021
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
    Inventors: Liguang Dai, Xiaowei Duan, Yanqing Yang, Xijie Liu, Hongjuan Li, Na Zhao, Yinghui Sun, Fansheng Kong, Jiuqing Zhang, Yizhong Zhu, Ling Yang, Fei Liu
  • Iridinesulfonamide Compound And Use Method Thereof
    Publication number: 20210155610
    Abstract: An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer.
    Type: Application
    Filed: March 22, 2017
    Publication date: May 27, 2021
    Inventors: Li ZHU, Yanqing YANG, Liguang DAI, Xiaowei DUAN, Zhao YANG, Hui ZHANG, Yuandong HU, Yong PENG, Yongxin HAN, Rui ZHAO, Xin TIAN, Shanchun WANG
  • Sultam Compound And Application Method Thereof
    Publication number: 20210047314
    Abstract: Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.
    Type: Application
    Filed: March 22, 2017
    Publication date: February 18, 2021
    Inventors: Li ZHU, Xiaowei DUAN, Liguang DAI, Zhao YANG, Yanqing YANG, Hui ZHANG, Yuandong HU, Yong PENG, Yongxin HAN, Rui ZHAO, Xin TIAN, Shanchun WANG
  • Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
    Patent number: 10829492
    Abstract: Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: November 10, 2020
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
    Inventors: Li Zhu, Yuandong Hu, Wei Wu, Liguang Dai, Xiaowei Duan, Yanqing Yang, Yinghui Sun, Yongxin Han, Yong Peng, Fansheng Kong, Hong Luo, Ling Yang, Hongjiang Xu, Meng Guo, Zhaobai Zhong, Shanchun Wang
  • MACROCYCLE CONTAINING AMINOPYRAZOLE AND PYRIMIDINE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20200291042
    Abstract: The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (1), a pharmaceutical composition thereof, and a use thereof in inhibiting tropornyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk.
    Type: Application
    Filed: August 23, 2018
    Publication date: September 17, 2020
    Inventors: Liguang DAI, Xiaowei DUAN, Yanqing YANG, Xijie LIU, Hongjuan LI, Na ZHAO, Yinghui SUN, Fansheng KONG, Jiuqing ZHANG, Yizhong ZHU, Ling YANG, Fei LIU
  • Pyrrolopyrimidine compound
    Patent number: 10561657
    Abstract: The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: February 18, 2020
    Assignees: Centaurus Biophrama Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd.
    Inventors: Li Zhu, Dengming Xiao, Yuandong Hu, Liguang Dai, Xiaowei Duan, Yinghui Sun, Yong Peng, Fansheng Kong, Hong Luo, Yongxin Han, Ling Yang, Shanchun Wang
  • AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR
    Publication number: 20190352306
    Abstract: Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.
    Type: Application
    Filed: October 27, 2017
    Publication date: November 21, 2019
    Inventors: Li ZHU, Yuandong HU, Wei WU, Liguang DAI, Xiaowei DUAN, Yanqing YANG, Yinghui SUN, Yongxin HAN, Yong PENG, Fansheng KONG, Hong LUO, Ling YANG, Hongjiang XU, Meng GUO, Zhaobai ZHONG, Shanchun WANG
  • PYRROLOPYRIMIDINE COMPOUND
    Publication number: 20190201403
    Abstract: The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.
    Type: Application
    Filed: December 15, 2015
    Publication date: July 4, 2019
    Inventors: Li Zhu, Dengming Xiao, Yuandong Hu, Liguang Dai, Xiaowei Duan, Yinghui Sun, Yong Peng, Fansheng Kong, Hong Luo, Yongxin Han, Ling Yang, Shanchun Wang